Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase II single-arm open-label study of nivolumab as maintenance therapy after
autologous stem cell transplantation in patients with Hodgkin lymphoma at risk of relapse or
progression.